Boron-containing lead compounds targeting human African trypanosomiasis

A collaboration with Anacor led to the identification of a potent lead series effective against trypanosomes in culture, as well as in an animal model of acute infection. CDIPD Director, James McKerrow, introduced Anacor to DNDi to facilitate further development of this series. With synthetic chemistry and PK support from Scynexis, a lead compound has been developed into a clinical candidate, oxaborole SCYX-7158. This drug candidate is now in clinical trials and was declared "Project of the Year 2011" by DNDi.